Finance

May 10 Quick Takes: Novavax sinks on vaccine submission delay; plus Alebund, Gennao, Therini, Singular Genomics and more

After closing down $15.50 (9%) to $160.50 Monday, Novavax Inc. (NASDAQ:NVAX) shed an additional 11% in after-hours trading following its announcement that the company will file for emergency authorization of its COVID-19 vaccine in 3Q21...

Financing Scandinavia; plus IP waivers, Long COVID & AAV pays: a BioCentury podcast

Scandinavia’s appetite for risk and strong foundation in basic research have given the region a robust translational environment and broad interest in investing in life sciences. But does that guarantee...

Abingworth builds on success of co-development deals with $582M fund

A run of successes from its first clinical co-development fund has allowed Abingworth to increase the size of its second fund 5x, enabling the firm to ramp up its number of and stake in new...

A look at aftermarket performance for 2021’s NASDAQ IPO class: Data Byte

With a postponement, a withdrawal and weakening aftermarket performance of NASDAQ IPOs, signs have begun to appear that investors’ long-robust appetite for new biotech listings has begun to wane. While stem cell transplantation company Talaris...

The Nordic Track for financing biotechs

A pharma history and healthy risk appetite has given Scandinavia a vibrant translational environment and broad interest in investing in life sciences. But easy money isn’t always the best money for building...

Engineered AAV plays lead gene therapy venture rounds: Data Byte

Venture funding is pouring into gene therapy companies, many of which are developing next-generation technologies to overcome the dosing, tissue selectivity, immunogenicity and manufacturing challenges of first-generation products.  Dyno Therapeutics Inc. became the latest member...

Amid flurry of financings for AAV plays, Dyno raises $100M series A led by a16z

The run of AAV company financings continues with Dyno’s $100 million series A round led by Andreessen Horowitz, which marks the third venture round for a capsid engineering company in eight days. ...

Biden’s IP pledge sinks vaccine makers’ shares

The Biden administration’s decision to support a WTO waiver of IP protections for COVID-19 vaccines led to an abrupt dive around 3:00 p.m. Eastern time for shares of vaccine developers such as Moderna and BioNTech...

Europe’s top venture fund-raisers in 2018-20: Data Byte

At least six European biotechs raised more than $100 million in 2018-20 and are still private, with Oxford Nanopore Technologies Ltd. topping the list at $314.6 million.  A further four companies raised nearly $100 million...

Funds fueling biotech-SPAC mergers: Data Byte

At least 30 biotechs have chosen to go public by merging with SPACs in the past two years, and the majority announced a hefty PIPE along with the deal. The largest aggregate amount raised in...

Record-setting series A for Denmark’s Adcendo clears path to POC

A €51 million ($62 million) series A round by Adcendo lands the Danish ADC company a spot among European biotech’s 15 largest series A rounds and sets the company up to carry its lead program through...

Werewolf, Vaccitech IPOs signal continued appetite for fresh biotech paper

A third of the way through 2021, appetite for new listings has allowed biopharmas to raise more than three times as much cash via NASDAQ IPOs as they did during the same period last year....

Arch pushing anti-CD47 into new settings with $105M series C round

Arch Oncology, the latest CD47-focused biotech to draw big money with its $105 million series C round, plans to use its new capital to broaden the clinical development program for AO-176 and add new pipeline...

Lukewarm reception for Rain, Impel as IPO queue swells further

The IPO queue continued to grow this week behind the two biotechs that began trading Friday, as Rain swiftly gave back early double-digit gains while Impel mostly traded close to its offering price. Both Rain...

April 21 Quick Takes: $50M for Sense Biodetection to expand portfolio; plus semaglutide, Porton, Seed Health, Rinri, Mestag, Lyndra

A $50 million series B round led by Koch Disruptive Technologies positions Sense Biodetection Ltd. to launch its Veros COVID-19 molecular test and build out a portfolio of tests for other indications via the U.K....